The effects of mangiferin (Mangifera indica L) in doxorubicin-induced cardiotoxicity in rats
Abstract
Aim The cardiotoxicity effect of doxorubicin (DOX), a widely used antitumor agent has restricted its clinical application. The aim of the current study was to explore the potential protective effect of mangiferin, a naturally occurring glucosylxanthone, that have antioxidant activity by its iron-complexing ability in mitochondria, against DOX-induced cardiac toxicity in rats in comparison with other antioxidants namely Sylimarin (SYL) and Vitamin E (VitE). Methods Mangiferin was given orally to rats at a dose of 50, and 100 mg/kg for 5 weeks, and DOX was injected at a total dose of 15 mg/kg. Cardiac toxicity was evaluated by lactate dehydrogenase and creatine kinase in the serum, malondialdehyde (MDA) level in plasma and cardiac tissue, and antioxidant enzyme superoxide dismutase (SOD) in cardiac tissue. Results Mangiferin protected against DOX-induced increased mortality and electrocardiogram abnormality and decreased biochemical markers of cardiac toxicity i. e., lactate dehydrogenase and creatine phosphokinase isoenzyme. In addition, elevation of plasma and cardiac tissue levels of MDA in response to DOX treatment were significantly attenuated. The reduction of cardiac activity of SOD was significantly reduced in contrast with the other antioxidant SYL and Vit E. Histopathologically, mangiferin treatment showed significant reduction in inflammatory cell number, fibrotic area, and necrotic foci as compared with DOX only-treated rats. Conclusion These results suggested that…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Mangiferin administration (50 or 100 mg/kg for 5 weeks) protects against doxorubicin-induced mortality and electrocardiogram abnormality, and decreases expression of biochemical cardiac toxicity markers dehydrogenase and creatine phosphokinase isoenzyme.
“Mangiferin administration (50 or 100 mg/kg for 5 weeks) also protects against doxorubicin-induced mortality and electrocardiogram abnormality, decreases the expression of biochemical cardiac toxicity markers, such as dehydrogenase and creatine phosphokinase isoenzyme (81).”
From Mangiferin: An effective therapeutic agent against several disorders (Review) (2018) · cites this paper as [81]
Cited by
Sorted by citations
Mangiferin: A natural miracle bioactive compound against lifestyle related disorders
Imran, M., Arshad, M. S., Butt, M. S., Kwon, J.-H., Arshad, M. U., & Sultan, M. T. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0449-y · Cited by 366 · see citing works
Mangiferin: A xanthonoid with multipotent anti‐inflammatory potential
Saha, S., Sadhukhan, P., & Sil, P. C. (2016) · BioFactors · doi:10.1002/biof.1292 · Cited by 159 · see citing works
Mangiferin: An effective therapeutic agent against several disorders (Review)
Du, S., Liu, H., Lei, T., Xie, X., Wang, H., He, X., Tong, R., & Wang, Y. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9529 · Cited by 139 · see citing works
“Mangiferin administration (50 or 100 mg/kg for 5 weeks) also protects against doxorubicin-induced mortality and electrocardiogram abnormality, decreases the expression of biochemical cardiac toxicity markers, such as dehydrogenase and creatine phosphokinase isoenzyme (81).”
Morozkina, S. N., Nhung Vu, T. H., Generalova, Y. E., Snetkov, P. P., & Uspenskaya, M. V. (2021) · Biomolecules · doi:10.3390/biom11010079 · Cited by 82 · see citing works
- Authors
- Arozal, W., Suyatna, F., Juniantito, V., Rosdiana, D., Amurugam, S., Aulia, R., Monayo, E., & Siswandi, R.
- Affiliations
- University of Indonesia (ID)
- IPB University (ID)
- Niigata University of Pharmacy and Medical and Life Sciences (JP)
- Venue
- Drug Research
- Publisher
- Georg Thieme Verlag KG
- Published
- 2014-11-26
- Volume
- 65
- Issue
- 11
- Pages
- 574-580
- ISSN
- 2194-9379 (ISSN-L)
- 2194-9387
- OpenAlex
- W2328175912
- Cited by
- 32
- References
- 0
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 1 · 2023: 4 · 2022: 3 · 2021: 2 · 2020: 5 · 2019: 2 · 2018: 2 · 2017: 3 · 2016: 5 · 2015: 1
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
- Health Sciences › Medicine › Complementary and alternative medicine › Mangiferin and Mango Extracts
- Physical Sciences › Materials Science › Biomaterials › Phytochemistry and Bioactive Compounds
- Keywords
- mangiferin, doxorubicin, cardiotoxicity, cardioprotection, antioxidant activity, iron chelation, malondialdehyde, superoxide dismutase, vitamin E, myocardial fibrosis, oxidative stress, mango
- MeSH terms
- Animals, Antibiotics, Antineoplastic, Antioxidants, Dose-Response Relationship, Drug, Doxorubicin, L-Lactate Dehydrogenase, Male, Malondialdehyde, Silymarin, Superoxide Dismutase, Vitamin E, Rats, Sprague-Dawley, Mangifera, Xanthones, Rats, Cardiotoxicity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
